Title: Bi-213-anti-EGFR-MAb therapy of recurrent bladder cancer – a pilot study
Authors: SCHEIDHAUER KLEMENSSEIDL C.BRUCHERTSEIFER FRANKAPOSTOLIDIS CHRISTOSAUTENRIETH MICHAELKURTZ FHORN THOMASSCHWAIGER MARKUSGSCHWEND J.E.D'ALESSANDRIA CPFOB CSENEKOWITSCH-SCHMIDTKE REINGARDMORGENSTERN ALFRED
Publisher: European Commission - Joint Resarch Centre
Publication Year: 2017
JRC N°: JRC106154
URI: http://nucmed.w3.kanazawa-u.ac.jp/symposium/tat10/
http://publications.jrc.ec.europa.eu/repository/handle/JRC106154
Type: Articles in periodicals and books
Abstract: Following transurethral resection of non-muscle-invasive bladder cancer (carcinoma in situ) and subsequent chemotherapy and treatment with Bacillus Calmette–Guérin (BCG), up to 40% of patients relapse within 5 years and need complete bladder excision. Therefore, new therapeutic strategies to combat tumor recurrence are needed. Because treatment of mice bearing intravesical human bladder cancer xenografts with Bi-213-anti-EGFR-MAb turned out highly efficient, the aim of this pilot study was to evaluate feasibility, safety and therapeutic efficacy of the α-emitter radioimmunoconjugate in recurrent bladder cancer patients.
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.